544 research outputs found
Therapieansprechen der palmoplantaren Pustulose auf Upadacitinib: eine Fallserie von fünf Patienten
No full textThe Δρομοδείχτης της Ελλάδος of 1824 and Athanasios Stageirites (Τίτλος περίληψης)
No full textσ. [281]-290Κείμενο στα ελληνικά με περίληψη στα αγγλικά με τον τίτλο: The Δρομοδείχτης της Ελλάδος of 1824 and Athanasios StageiritesThe article first examines the close relationship between the publication “Δρομοδείχτης της Ελλάδος” [1824] and the publication “Ηπειρωτικά” (1819) by Athanasios Stageirites and then suggests that Athanasios Stageirites is the likeliest author of the “Δρομοδείχτης της Ελλάδος”.Δωδώνη: Τεύχος Πρώτο: επιστημονική επετηρίδα του Τμήματος Ιστορίας και Αρχαιολογίας της Φιλοσοφικής Σχολής του Πανεπιστημίου Ιωαννίνων; Τόμ. 43-44 (2014-2015
Dataset in support of the Southampton doctoral thesis 'The boatbuilding tradition of the Aegean during the Late Neolithic – Early Bronze Age periods. Typological classification, digital reconstruction and seakeeping assessment'
No full textDataset in support of the Southampton doctoral thesis 'The boatbuilding tradition of the Aegean during the Late Neolithic – Early Bronze Age periods. Typological classification, digital reconstruction and seakeeping assessment' Appendix D - Resistance data and Appendix C - Stability data.
This dataset is focused on two appendices:
Appendix D - Resistance data. D.1 Resistance data produced by the author via MAXSURF Resistance for this thesis.
Appendix C - Stability data
C1. Stability data – STIX and ISO criteria, produced by the author via MAXSURF Stability software for his thesis
This research was funded by Southampton Marine and Maritime Institute (SMMI), Vice-Chancellor's Scholarship, Greek Archaeological Committee UK (GACUK)
</span
Expression of CD152 (CTLA-4) on T lymphocytes in melanoma and in blood after hyperthermia
No full textIm ersten Teil dieser Arbeit wurde gezeigt, dass ein Großteil der tumorinfiltrierden Lymphozyten (TIL) bei Primärmelanomen hohe Expressionswerte des anti-inflammatorischen T-Zellmarkers CTLA-4 aufweist. Der in klinischen Studien bereits gezeigte stimulierende Effekt für die Tumorantwort durch die Blockade von CTLA-4 mittels monoklonaler Antikörper mag daher zumindest teilweise durch die Reaktivierung dieser TIL bedingt sein. Ob es sich bei den beschriebenen TIL um regulatorische T-Zellen (Treg) handelt, ist noch zu zeigen.
Im zweiten Teil dieser Arbeit wurde die CTLA-4-Expression von PBL (periphere Blutlymphozyten) von Hyperthermie-behandelten Tumorpatienten gemessen. Dabei zeigte sich ein Expressionsmaximum am sechsten Tag nach Hyperthermie. Eine zusätzliche therapeutische CTLA-4-AK-Gabe nach Hyperthermie sollte daher an diesem Tag oder früher erfolgen, um einen größtmöglichen therapeutischen Nutzen zu erzeugen.
Im dritten Teil dieser Arbeit wurde ein Computer-gestütztes Messsystem für die CTLA-4-Expression von PBL etabliert, welche eine Alternative zur bislang manuellen Auszählung darstellt.We could show that a major part of tumor infiltrating lymphocytes (TIL) of primary melanoma shows a high expression of the anti-inflammatory molecule CTLA-4. The (by clinical studies well-known known) immunostimulatory effect of monoclonal antibodies against CTLA-4 might be (at least partly) explained by reactivation of these TIL. If the decribed TIL are regulatory T cells (Treg) has still to be shown.
Furthermore we measured the CTLA-4 expression of periphery blood lymphocytes (PBL) of hyperthermia treated tumor patients. We could detect a peak of CTLA-4 expression at day 6 after hyperthermia. If an additional CTLA-4 antibody therapy was planned in hyperthermia patients, we consequently suggest the application at day 6 after hyperthermia to reach best therapeutic results.
Finally we established a computer based measurement system for CTLA-4 expression on PBL. That system might be an alternative to the manual method
Peak power reduction algorithms in asymmetric digital subscriber line modems
No full textThesis (M.Eng.)--Massachusetts Institute of Technology, Dept. of Electrical Engineering and Computer Science, 2000.Includes bibliographical references (leaves 94-96).This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.This thesis investigates peak-to-average ratio (PAR) reduction techniques for multicarrier modulation systems, such as discrete multitone (DMT) modems and orthogonal frequency-division multiplexed (OFDM) terrestrial broadcast transmitters. Through simulation and test implementation on a state-of-the-art programmable ADSL development platform, this thesis pursues a suitable solution for minimizing PAR given the resources of a programmable platform. This solution is integrated as a prototype implementation into a fully-functional ADSL modem and optimized for maximum PAR reduction performance within modem complexity constraints.by Athanasios Dimitri Dousis.M.Eng
Homophobic Statements, a Bishop, and the Limits of Freedom of Expression. An In-Depth Commentary on ECtHR 31.08.2023, Amvrosios-Athanasios Lenis v. Greece, no. 47833/20
No full textDichiarazioni omofobe, un vescovo e i limiti della libertà di espressione. Un commento approfondito su CEDU 31.08.2023, Amvrosios-Athanasios Lenis v. Greece, no. 47833/20.
ABSTRACT: The decision of the ECtHR of 31.08.2023, Amvrosios-Athanasios Lenis v. Greece (no. 47833/20), is a further step toward an increasingly dense jurisprudence on “hate speech” and the limits of freedom of expression. The public proclamation of religious doctrines that are in conflict with the values of the contracting States enshrined in the ECHR is protected to a certain extent by the fundamental right of freedom of religion and belief. However, the qualification of a statement as religious does not justify “hate speech.” The AUTHOR shows the tension between freedom of religion, freedom of expression, and protection against discrimination, and analyzes the decision against the backdrop of Article 17 of the ECHR (prohibition of abuse of rights).
SOMMARIO: 1. Preliminary Remarks - 2. The Concept of Hate Speech - 3. The Facts of the Case - 4. The Procedure and Reasoning of the Court - 4.1 The ECtHR’s Preliminary Considerations on Fundamental Rights - 4.2 Legal assessment - 4.3 Some Remarks on (the Non-Invoked) Article 9 of the ECHR - 5. Concluding Remarks
Efficacy and safety of topical tacrolimus microemulsion applied twice daily in patients with mild to moderate scalp psoriasis
No full textIntroduction:
Involvement of the scalp is common in psoriasis and severely affects the quality of life of those affected. It is difficult to treat and places special demands on the galenics of a drug formulation. Tacrolimus is a calcineurin inhibitor and is approved as an ointment formulation for the treatment of atopic dermatitis. The efficacy and safety of topically applied tacrolimus have also been studied and proven for psoriasis. However, no proprietary pharmaceutical product is currently approved for this indication.
Methods:
A multicenter, double-blind, vehicle-controlled phase 3 study was conducted to evaluate the efficacy and safety of 0.1% tacrolimus microemulsion when applied topically twice daily in 128 patients independently of sex with scalp psoriasis.
Results:
The primary efficacy analysis showed a scalp Investigator Global Assessment (s-IGA) of 0 (absence of disease) or 1 (very mild disease) at 8 weeks in 28.6% of subjects in the tacrolimus group, indicating a significantly better response (p = 0.0476, chi-square test) versus 12.7% of subjects in the placebo group (difference of 15.9%-points). The Dermatology Life Quality Index (DLQI) improved over time and was more pronounced in the group treated with tacrolimus-containing microemulsion than in the placebo group, but showed no statistically significant difference after 8 weeks of use (p = 0.193, ANCOVA). The safety analysis revealed no evidence of cutaneous side effects other than those known. Toxicologically relevant serum levels of tacrolimus could be excluded.
Conclusion:
The study data show that 0.1% tacrolimus microemulsion has good efficacy and safety in the treatment of scalp psoriasis
- …
